Evidence map›Paper›PMID 40933190›Full record

ArticleFrontiers in neuroscience2025

A lightweight triple-modal fusion network for progressive mild cognitive impairment prediction in Alzheimer's disease.

Xiangyu Shen, Xiangyang Hu, Renfeng Zhang, Yunzhan Fu, Jiamin Xu, Degang Lyu, Hongbiao Xie, Deen Shi, Changsheng Shi, Lisi Li and 1 more

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiangyu ShenHangzhou Dianzi University, Hangzhou, China.
Xiangyang HuHangzhou Dianzi University, Hangzhou, China.
Renfeng ZhangDepartment of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Yunzhan FuHangzhou Dianzi University, Hangzhou, China.
Jiamin XuHangzhou Dianzi University, Hangzhou, China.
Degang LyuDepartment of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College, Ji'nan University, The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China.
Hongbiao XieHangzhou Dianzi University, Hangzhou, China.
Deen ShiDepartment of Radiology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Changsheng ShiDepartment of Interventional Vascular Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Lisi LiShenzhen Hospital of Southern Medical University, Shenzhen, China.
Yuantong GaoDepartment of Radiology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: As a progressive neurodegeneration, Alzheimer's disease (AD) represents the primary etiology of dementia among the elderly. Early identification of individuals with mild cognitive impairment (MCI) who are likely to convert to AD is essential for timely diagnosis and therapeutic intervention. Although multimodal neuroimaging and clinical data provide complementary information, existing fusion models often face challenges such as high computational complexity and limited interpretability. Methods: To address these limitations, we introduce TriLightNet, an innovative lightweight triple-modal fusion network designed to integrate structural MRI, functional PET, and clinical tabular data for predicting MCI-to-AD conversion. TriLightNet incorporates a hybrid backbone that combines Kolmogorov-Arnold Networks with PoolFormer for efficient feature extraction. Additionally, it introduces a Hybrid Block Attention Module to capture subtle interactions between image and clinical features and employs a MultiModal Cascaded Attention mechanism to enable progressive and efficient fusion across the modalities. These components work together to streamline multimodal data integration while preserving meaningful insights. Results: Extensive experiments conducted on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset demonstrate the effectiveness of TriLightNet, showcasing superior performance compared to state-of-the-art methods. Specifically, the model achieves an accuracy of 81.25%, an AUROC of 0.8146, and an F1-score of 69.39%, all while maintaining reduced computational costs. Discussion: Furthermore, its interpretability was validated using the Integrated Gradients method, which revealed clinically relevant brain regions contributing to the predictions, enhancing its potential for meaningful clinical application. Our code is available at https://github.com/sunyzhi55/TriLightNet.

Indexed as

Alzheimer's diseaseattention mechanismintegrated gradientslightweight neural networkmild cognitive impairmenttriple-modal fusion

Identifiers

PMID40933190
PMCPMC12417529

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.